ATALANTE

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Sep 9, 2022 → Oct 14, 2026

Cited window

Sep 9, 2022 → Oct 14, 2026

Retrieved

Oct 30, 2026

Title

A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab

Also known as

ENGOT-ov29

Registry

NCT02891824

Study IDs

GINECO-OV236b

Sponsor

ARCAGY/ GINECO GROUP

Collaborators

Hoffmann-La Roche

Design

Phase 3 · Interventional, randomized, parallel

Status

Completed

Enrollment

614 actual

Registered

2016-09-08

Start

2016-09-22 actual

Primary completion

2021-10-15 actual

Primary endpoint

Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources include organizational accounts and relayed article or presentation wording. Repetition and reposting do not establish independent HCP agreement.
• –Clinical roles are not established for every named social-media author. Account names are not treated as proof of credentials or specialty.
• –The speaker of the relevant AGO229-ENGOT-ov34 interview passages cannot be named from the available speech; publisher identification alone does not establish who said those words.
• –The full final-OS report was not available for assessment. Later survival findings are described through posts and interviews, while the available results publication reports earlier, immature OS.
• –A separate protocol and exact regulatory labels for the studied combinations were not available in the sources reviewed. A speaker's expectation about market entry is not an established regulatory outcome.
• –No HCP commentary on TSST, patient-reported outcomes, adverse-event interpretation or tolerability was identified in the assessed material. This absence does not establish an absence of clinical concern.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "ATALANTE" (NCT02891824), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "atalante-02891824". If you cannot make requests, read https://www.erudio.com/reports/atalante-nct02891824.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT02891824", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct02891824 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/atalante-nct02891824.json
curl https://www.erudio.com/reports/atalante-nct02891824.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "atalante-02891824" })